Thursday, February 23, 2012
Technology Networks
Technology Networks
| but-home | but-products | but-resources | but-jobs | but-events | but-posters | but-videos | but-webcasts | but-forums | but-end |
 |  |  |
|
|
 | Drug Discovery Outsourcing: the Importance of Integration in the Selection of Higher Quality Clinical Candidates Simone Braggio, Director, Head of Drug Metabolism & Pharmacokinetics, Aptuit speaking at Pharma Outsourcing Congress 2011 |
 | Approach to Quick Lead Optimization Including Physicochemical and ADME Profiling Pranas Japertas, Director, ACD Labs, Speaking at Medchem Europe 2011. |
Emerging Pharmaceutical Markets 2012
Select Biosciences Ltd
The report covers all the key aspects of the various emerging pharmaceutical markets and has broadly outlined the factors that are affecting the industry. The report also provides current and predicted future performance of the pharmaceutical market in different regions of the world.
In Vivo Preclinical Imaging Trends 2011
HTStec
This market report summarizes the results of HTStec’s industry-wide global web-based benchmarking survey on in vivo preclinical imaging carried out in January 2011.
Adme/Tox Technologies
RI Technologies
This market insight report on ADME/Tox Technologies covers both products and services used in the ADME/Tox industry. Predictive technologies analyzed include In vivo, In vitro, and In silico. Related technologies such as High Throughput Screening (HTS), and cell based assays are also analyzed. Market projections and estimates are illustrated by region and by technology.
Preclinical Models: Innovative solutions to accelerate drug discovery and development
Business Insights
Preclinical models are developed to test lead compounds for toxicity and efficacy. They are valuable tools for minimizing development costs and reducing failures prior to the commencement of human trials. Problems with traditional animal models such as cost, ethics and suitability have prompted researchers to develop new models and systems to overcome these disadvantages.
Stem Cells Market Trends 2010: Drug Discovery/Toxicity Screening and Regenerative Medicine
Select Biosciences Ltd
This market trends report from Select Biosciences presents the results from our latest industry tracking completed in March 2010. The data presented herein are based on primary market surveys from a worldwide respondent pool of industry participants active in the stem cells field.
Select Biosciences Ltd
The report covers all the key aspects of the various emerging pharmaceutical markets and has broadly outlined the factors that are affecting the industry. The report also provides current and predicted future performance of the pharmaceutical market in different regions of the world.
In Vivo Preclinical Imaging Trends 2011
HTStec
This market report summarizes the results of HTStec’s industry-wide global web-based benchmarking survey on in vivo preclinical imaging carried out in January 2011.
Adme/Tox Technologies
RI Technologies
This market insight report on ADME/Tox Technologies covers both products and services used in the ADME/Tox industry. Predictive technologies analyzed include In vivo, In vitro, and In silico. Related technologies such as High Throughput Screening (HTS), and cell based assays are also analyzed. Market projections and estimates are illustrated by region and by technology.
Preclinical Models: Innovative solutions to accelerate drug discovery and development
Business Insights
Preclinical models are developed to test lead compounds for toxicity and efficacy. They are valuable tools for minimizing development costs and reducing failures prior to the commencement of human trials. Problems with traditional animal models such as cost, ethics and suitability have prompted researchers to develop new models and systems to overcome these disadvantages.
Stem Cells Market Trends 2010: Drug Discovery/Toxicity Screening and Regenerative Medicine
Select Biosciences Ltd
This market trends report from Select Biosciences presents the results from our latest industry tracking completed in March 2010. The data presented herein are based on primary market surveys from a worldwide respondent pool of industry participants active in the stem cells field.
Cholinesterases, a Target of Pharmacology and Toxicology
This review’s main focus is on cholinesterases as targets of toxins and drugs. The biochemistry of AChE and BuChE is also discussed. Drugs and toxins are divided in chapters according to target sites.
Estimation of drug-metabolizing capacity by CYP-genotyping and CYP-expression
The lack of therapeutic effect of drugs or the appearance of undesired side-effects is partly caused by differences or changes in drug metabolism. This work aims to introduce an approach of combining CYP-genotyping and CYP-phenotyping tools to estimate patients’ drug-metabolizing capacity.
Positive Data on AEOL 11207 in Pre-Clinical Epilepsy Model
Aeolus Pharmaceuticals compound significantly decreases both the frequency and duration of spontaneous seizures; increase in average life span; protected against neuronal death.
NanoInk Announces Launch of Contract Services Program for Live Single Cell Assay Work
Service offering expected to advance research programs involved with toxicity assessment, high content screening, and cell-cell communication.
Anacor Pharmaceuticals Announces Its Partner GSK Voluntarily Paused Clinical Trials
Trials paused due to a recently identified microbiological finding in a small number of patients in the Phase 2b trial of GSK '052 for the treatment of complicated urinary tract infections (cUTI).
UT Southwestern Research Suggests New Way to Ensure Effectiveness of TB Treatment
By using a “glass mouse” research model study founds that multidrug-resistant TB is caused in patients by speedy drug metabolism.
Quantum Genomics gets Approval from the Patients' Protection Committee
The "Comité de Protection des Personnes (Ile de France VIII)" has approved the first clinical trial in humans of Quantum’s leading compound QGC001; trials are expected to start in early 2012.
The Economist Accused of Inaccurate Coverage of Cell Phone and Wireless Risks
Specialists in public health, oncology, neurosurgery, electronic engineering, toxicology, cardiology and epidemiology have published a critique of an opinion piece published in The Economist (9/3/11), “Worrying about Wireless”.
Companies, Regulatory Authorities Can Spare Millions of Animals in Labs with New OECD Test Method
“Two-generation” animal test for reproductive toxicity replaced with a new “extended one-generation” method.
US Tox21 to begin screening 10,000 chemicals
A high-speed robotic screening system, aimed at protecting human health by improving how chemicals are tested in the United States, has begun testing the compounds for potential toxicity.
This review’s main focus is on cholinesterases as targets of toxins and drugs. The biochemistry of AChE and BuChE is also discussed. Drugs and toxins are divided in chapters according to target sites.
Estimation of drug-metabolizing capacity by CYP-genotyping and CYP-expression
The lack of therapeutic effect of drugs or the appearance of undesired side-effects is partly caused by differences or changes in drug metabolism. This work aims to introduce an approach of combining CYP-genotyping and CYP-phenotyping tools to estimate patients’ drug-metabolizing capacity.
Positive Data on AEOL 11207 in Pre-Clinical Epilepsy Model
Aeolus Pharmaceuticals compound significantly decreases both the frequency and duration of spontaneous seizures; increase in average life span; protected against neuronal death.
NanoInk Announces Launch of Contract Services Program for Live Single Cell Assay Work
Service offering expected to advance research programs involved with toxicity assessment, high content screening, and cell-cell communication.
Anacor Pharmaceuticals Announces Its Partner GSK Voluntarily Paused Clinical Trials
Trials paused due to a recently identified microbiological finding in a small number of patients in the Phase 2b trial of GSK '052 for the treatment of complicated urinary tract infections (cUTI).
UT Southwestern Research Suggests New Way to Ensure Effectiveness of TB Treatment
By using a “glass mouse” research model study founds that multidrug-resistant TB is caused in patients by speedy drug metabolism.
Quantum Genomics gets Approval from the Patients' Protection Committee
The "Comité de Protection des Personnes (Ile de France VIII)" has approved the first clinical trial in humans of Quantum’s leading compound QGC001; trials are expected to start in early 2012.
The Economist Accused of Inaccurate Coverage of Cell Phone and Wireless Risks
Specialists in public health, oncology, neurosurgery, electronic engineering, toxicology, cardiology and epidemiology have published a critique of an opinion piece published in The Economist (9/3/11), “Worrying about Wireless”.
Companies, Regulatory Authorities Can Spare Millions of Animals in Labs with New OECD Test Method
“Two-generation” animal test for reproductive toxicity replaced with a new “extended one-generation” method.
US Tox21 to begin screening 10,000 chemicals
A high-speed robotic screening system, aimed at protecting human health by improving how chemicals are tested in the United States, has begun testing the compounds for potential toxicity.
Gentronix Expands Specialist Sales Team in US and Europe
Expansion of sales teams with the appointments of Dorothy Zelent and Simon Johns.
Ferrer Announces Best-in-Class Results in Phase I for Lorediplon in Insomnia
Ferrer now seeking development partners for Lorediplon that has demonstrated a highly promising efficacy, safety and tolerability profile.
The Hamner Institutes for Health Sciences and Alexandria Real Estate Equities, Inc. Announce Collaboration
The Research Triangle Park Collaboration Consortium is a new and highly unique hub that will bring together North Carolina's world-renowned universities, innovative public and private companies, and leading international institutions.
AiCuris Drug Letermovir Meets Primary Efficacy Endpoints in Phase 2 For Human Cytomegalovirus Prophylaxis
Trial shows a dose-dependent effect on the prevention of HCMV re-activation/re-infection and an excellent tolerability.
Ironwood Pharmaceuticals Prices Public Offering of Common Stock
Company announces the pricing of an underwritten public offering of 5,250,000 shares of its Class A common stock at a price of $15.09 per share to the public.
Amicus Therapeutics Presents Preclinical Studies of Chaperone AT3375 for Gaucher Disease
The company presented preclinical studies of AT3375 as a monotherapy and in combination with enzyme replacement therapy for Gaucher disease during the 8th Annual Lysosomal Disease Network WORLD Symposium.
Nanoink Announces Launch of Contract Services Program for Live Single Cell Assay Work
Service offering expected to advance research programs involved with toxicity assessment, high content screening, and cell-cell communication.
Norwich Expands Capabilities for Phase I-III Clinical Trials
Growing market demand leads to expansion at two research facilities.
Asterand Subsidiary BioSeek and US EPA Expand ToxCast™ Collaboration
BioSeek’s BioMAP® systems platform used to predict toxicity of environmental and other compounds on human health.
Affectis Granted Patent for AFC-5128, other P2X7 Antagonists
The pharmaceutical company announced that the European Patent Office has granted a key patent for its oral brain-penetrant P2X7 antagonist AFC-5128 for the treatment of neuropathic pain and MS.
Expansion of sales teams with the appointments of Dorothy Zelent and Simon Johns.
Ferrer Announces Best-in-Class Results in Phase I for Lorediplon in Insomnia
Ferrer now seeking development partners for Lorediplon that has demonstrated a highly promising efficacy, safety and tolerability profile.
The Hamner Institutes for Health Sciences and Alexandria Real Estate Equities, Inc. Announce Collaboration
The Research Triangle Park Collaboration Consortium is a new and highly unique hub that will bring together North Carolina's world-renowned universities, innovative public and private companies, and leading international institutions.
AiCuris Drug Letermovir Meets Primary Efficacy Endpoints in Phase 2 For Human Cytomegalovirus Prophylaxis
Trial shows a dose-dependent effect on the prevention of HCMV re-activation/re-infection and an excellent tolerability.
Ironwood Pharmaceuticals Prices Public Offering of Common Stock
Company announces the pricing of an underwritten public offering of 5,250,000 shares of its Class A common stock at a price of $15.09 per share to the public.
Amicus Therapeutics Presents Preclinical Studies of Chaperone AT3375 for Gaucher Disease
The company presented preclinical studies of AT3375 as a monotherapy and in combination with enzyme replacement therapy for Gaucher disease during the 8th Annual Lysosomal Disease Network WORLD Symposium.
Nanoink Announces Launch of Contract Services Program for Live Single Cell Assay Work
Service offering expected to advance research programs involved with toxicity assessment, high content screening, and cell-cell communication.
Norwich Expands Capabilities for Phase I-III Clinical Trials
Growing market demand leads to expansion at two research facilities.
Asterand Subsidiary BioSeek and US EPA Expand ToxCast™ Collaboration
BioSeek’s BioMAP® systems platform used to predict toxicity of environmental and other compounds on human health.
Affectis Granted Patent for AFC-5128, other P2X7 Antagonists
The pharmaceutical company announced that the European Patent Office has granted a key patent for its oral brain-penetrant P2X7 antagonist AFC-5128 for the treatment of neuropathic pain and MS.
 | ||||||||||||||||
|
Validation of an Automated Cell-Based Bioluminescent TNFa Blocker Bioassay
BioTek Instruments
TNFa blocker biopharmaceuticals represent an important and successful class of protein drugs used in the treatment of several autoimmune diseases. Bioassays are indispensible tools in biopharmaceutical drug development and commercialization that are used to quantify biological activity and stability of drugs or drug candidates. The automation of these assays can serve to create an accurate, robust process which can allow the researcher to perform other more important functions.
Modeling Disposition of Sotalol following Intravenous and Oral Administration in Healthy Adult Subjects
Simulations Plus
Sotalol is a non specific adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmia. Its absorption, distribution and systemic PK or, collectively, ‘disposition’ was modeled and simulated using GastroPlus™ v7.0. Biopharmaceutical properties were obtained from in silico predictions and in vitro measurements.
Predicting hERG Potassium Channel Affinity with Artificial Neural Network Ensembles
Simulations Plus
Modeling hERG inhibition has gained significant popularity since 2005, when the FDA recognized the correlation between hERG inhibition and a prolonged QT interval by issuing guidance for the evaluation of new non-antiarrythmic drugs against the hERG channel.Long QT syndrome or LQTS is a risk factor for ventricular tachyarrhythmias and sudden death.
Predicting Sites of Metabolism with Artificial Neural Network Ensembles
Simulations Plus
Hepatic first-pass metabolism of many drugs and pro drugs plays a key role in their oral bioavailability. The human cytochrome P450 enzymes are responsible for the metabolism of most drugs. Knowledge of likely sites of metabolic attack in a drug molecule can aid in designing out unwanted metabolic liabilities early on in the drug discovery process, as well as in the design of pro drugs where metabolic transformation is desired.
Live Cell Beating Assay Using Human iPSC-derived Cardiomyocytes for Evaluation of Drug Efficacy and Toxicity
Molecular Devices
A large percentage of new drugs fail in clinical studies due to cardiac toxicity. Development of highly predictive in vitro assays suitable for screening, safety assessment or other environments is therefore extremely important for drug development. Human cardiomyocytes derived from stem cell sources can greatly accelerate the discovery of cardiac drugs and improve drug safety by offering more clinically relevant cell-based models than those presently available.
Quantification of cytokines on the SpectraMax® Paradigm® Multi-Mode Microplate Detection Platform using Alpha Technology
Molecular Devices
Inflammation is accompanied by increased endothelial chemokine production and adhesion molecule expression, which may result in an extensive neutrophil infiltration. As such, the search for novel anti-inflammatory substances able to downregulate these parameters, as well as tissue damage, holds therapeutic promise.
GALAS Modeling Methodology Applications In The Prediction Of Drug Metabolism Related Properties
ACD Labs
Analytical identification of metabolites for a drug candidate is usually a time consuming and low-throughput task and is performed only at the later phases of drug development. Therefore the possibility to predict possible sites of human liver microsomal (HLM) metabolism using in silico techniques would be a very attractive feature for any medicinal chemist.
Effective Use of In-Silico Tools in Lead Optimization
ACD Labs
Of all the challenges facing medicinal chemists in general, one of the most significant must be transforming an active molecule into a viable drug. Lead optimization efforts are guided by a combination of factors, such as potency, ease of synthesis, patentability concerns, specific synthetic constrains of the interaction with the target, as well as the lead’s toxicity and ADME properties.
A Weight-of-Evidence Approach to Prioritisation based on Consensus across Multiple Sources of Information
(1) Douglas Connect, (2) Leadscope, (3) IdeaConsult, (4) Pharmatrope
We present the results of initial work carried out within the OpenToxLink Virtual Organization, applying a Weight-of-Evidence (WoE) approach based on consensus across multiple sources of information for the prediction of adverse effects of a large set of potential antimalarial compounds. The work was carried out as part of the EU FP7 project SYNERGY, evaluating the support of decision dashboards and event-driven collaborative research of software developed within SYNERGY.
Three-dimensional quantitative structure-activity relationship analysis and ADME predictions of guanylhydrazone coactivator binding inhibitors of estrogen receptors
Würzburg University
The estrogen receptors (ER) refer to a group of the nuclear hormone receptor superfamily of ligand-mediated transcriptional factors. Over expression of this type of receptors leads to a breast cancer progression. Hormone-responsive breast cancer develops resistance to conventional anti-cancer therapy, and this becomes a major problem in a breast cancer therapy.
BioTek Instruments
TNFa blocker biopharmaceuticals represent an important and successful class of protein drugs used in the treatment of several autoimmune diseases. Bioassays are indispensible tools in biopharmaceutical drug development and commercialization that are used to quantify biological activity and stability of drugs or drug candidates. The automation of these assays can serve to create an accurate, robust process which can allow the researcher to perform other more important functions.
Modeling Disposition of Sotalol following Intravenous and Oral Administration in Healthy Adult Subjects
Simulations Plus
Sotalol is a non specific adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmia. Its absorption, distribution and systemic PK or, collectively, ‘disposition’ was modeled and simulated using GastroPlus™ v7.0. Biopharmaceutical properties were obtained from in silico predictions and in vitro measurements.
Predicting hERG Potassium Channel Affinity with Artificial Neural Network Ensembles
Simulations Plus
Modeling hERG inhibition has gained significant popularity since 2005, when the FDA recognized the correlation between hERG inhibition and a prolonged QT interval by issuing guidance for the evaluation of new non-antiarrythmic drugs against the hERG channel.Long QT syndrome or LQTS is a risk factor for ventricular tachyarrhythmias and sudden death.
Predicting Sites of Metabolism with Artificial Neural Network Ensembles
Simulations Plus
Hepatic first-pass metabolism of many drugs and pro drugs plays a key role in their oral bioavailability. The human cytochrome P450 enzymes are responsible for the metabolism of most drugs. Knowledge of likely sites of metabolic attack in a drug molecule can aid in designing out unwanted metabolic liabilities early on in the drug discovery process, as well as in the design of pro drugs where metabolic transformation is desired.
Live Cell Beating Assay Using Human iPSC-derived Cardiomyocytes for Evaluation of Drug Efficacy and Toxicity
Molecular Devices
A large percentage of new drugs fail in clinical studies due to cardiac toxicity. Development of highly predictive in vitro assays suitable for screening, safety assessment or other environments is therefore extremely important for drug development. Human cardiomyocytes derived from stem cell sources can greatly accelerate the discovery of cardiac drugs and improve drug safety by offering more clinically relevant cell-based models than those presently available.
Quantification of cytokines on the SpectraMax® Paradigm® Multi-Mode Microplate Detection Platform using Alpha Technology
Molecular Devices
Inflammation is accompanied by increased endothelial chemokine production and adhesion molecule expression, which may result in an extensive neutrophil infiltration. As such, the search for novel anti-inflammatory substances able to downregulate these parameters, as well as tissue damage, holds therapeutic promise.
GALAS Modeling Methodology Applications In The Prediction Of Drug Metabolism Related Properties
ACD Labs
Analytical identification of metabolites for a drug candidate is usually a time consuming and low-throughput task and is performed only at the later phases of drug development. Therefore the possibility to predict possible sites of human liver microsomal (HLM) metabolism using in silico techniques would be a very attractive feature for any medicinal chemist.
Effective Use of In-Silico Tools in Lead Optimization
ACD Labs
Of all the challenges facing medicinal chemists in general, one of the most significant must be transforming an active molecule into a viable drug. Lead optimization efforts are guided by a combination of factors, such as potency, ease of synthesis, patentability concerns, specific synthetic constrains of the interaction with the target, as well as the lead’s toxicity and ADME properties.
A Weight-of-Evidence Approach to Prioritisation based on Consensus across Multiple Sources of Information
(1) Douglas Connect, (2) Leadscope, (3) IdeaConsult, (4) Pharmatrope
We present the results of initial work carried out within the OpenToxLink Virtual Organization, applying a Weight-of-Evidence (WoE) approach based on consensus across multiple sources of information for the prediction of adverse effects of a large set of potential antimalarial compounds. The work was carried out as part of the EU FP7 project SYNERGY, evaluating the support of decision dashboards and event-driven collaborative research of software developed within SYNERGY.
Three-dimensional quantitative structure-activity relationship analysis and ADME predictions of guanylhydrazone coactivator binding inhibitors of estrogen receptors
Würzburg University
The estrogen receptors (ER) refer to a group of the nuclear hormone receptor superfamily of ligand-mediated transcriptional factors. Over expression of this type of receptors leads to a breast cancer progression. Hormone-responsive breast cancer develops resistance to conventional anti-cancer therapy, and this becomes a major problem in a breast cancer therapy.
BlueScreen HC - A Luminescence Based, High-Throughput, In Vitro Genotoxicity Assay
BMG LABTECH
The BlueScreen HC assay from Gentronix utilizes a luminescence-based reporter system to measure genotoxicity. The assay generates positive results e.g for direct-acting mutagens and clastogens and correct negative results for non-carcinogens. In addition, reduced cell proliferation, a measure of cytotoxicity, is assessed, too. Using the FLUOstar Omega microplate reader from BMG LABTECH the BlueScreen HC assay has been shown to be fast, accurate and reproducible.
A Fast and Simple Method For Measuring P-Glycoprotein (Pgp) Inhibition
BMG Labtech
Pgp expression has been linked to the effl ux of chemotherapeutic drugs in human cancers leading to multidrug resistance. Pgp activity can also result in low oral absorption and poor brain penetration. Interaction of drugs with the Pgp may also cause an increase in toxicity of co-administered compounds.
Pipetting performance of Thermo Scientific Finnpipette F2 in combination with Thermo Scientific Finntip Flex
Thermo Fisher Scientific
The Finnpipette® F2 product family has been designed by taking into account the demands of today´s laboratory work and the require¬ments of the end users. It offers superior comfort, performance, reliability and repeatability in one of the lightest pipettes available.
Using a Thermo Scientific Microplate Photometer to Choose an Optimum Reagent for Cytotoxicity Assays
Thermo Fisher Scientific
A number of different reagents can be used to perform photometric cell proliferation and viability assays. A microplate photometer can quickly determine which reagent is the best choice for an assay and then optimize the assay. Significant time savings and productivity gains can be achieved with this tool.
Ergonomics and Usability Study of Thermo Scientific Finnpipette F1 and F2 Pipettes
Thermo Fisher Scientific
The objective of the study was to evaluate the ergonomics and usability of six manual, singlechannel pipettes. This was done by measuring the load and strain symptoms exhibited by workers’ muscles and joints, and evaluating the usability features of pipettes in a simulated work situation.
Antimicrobial Properties of Thermo Scientific Finnpipette F1 Compared to Traditional Pipettes
Thermo Fisher Scientific
In this application note the antimicrobial properties of the Thermo Scientific Finnpipette F1 were compared to traditional pipettes without antimicrobial treatment. The experiments were performed by an independent laboratory (Institut für Biotechnische Forschung und Entwicklung Graf GmbH, Kirkel-Limbach, Germany).
Reproducible Dispensing of Live Cells with the Thermo Scientific Multidrop Combi Reagent Dispenser
Thermo Fisher Scientific
High throughput cell-based assays are an important part of drug screening, and successfully dispensing viable cells is a key step in the process. Automated reagent dispensers are used to achieve higher throughput in the screening laboratories. Dispense must not only be quick, it must also be gentle enough to ensure cell viability.
Device Qualification of the Thermo Scientific Finnpipette Novus Electronic Pipette (IQ/OQ/PQ)
Thermo Fisher Scientific
During device qualification, one verifies and documents whether the equipment, in this case a pipette, is reliable and capable of fulfilling the requirements of its intended use. All qualification activities are fully documented according to pertinent quality and regulatory requirements and signed by authorized personnel.
Use of Thermo Scientific Finnpipette Novus Electronic Pipettes for Accurate and Efficient Preparation of Standard Curves
Thermo Fisher Scientific
This application note discusses the use of a Thermo Scientific Finnpipette Novus Electronic Pipette for the preparation of standard curves. With 10 different functions, the versatile Novus Electronic pipette can perform most every standard curve required. The pipette’s performance was compared to a manual Thermo Scientific Finnpipette model to determine if there were appreciable differences in pipetting speed and accuracy during curve preparation.
MycoAlert Mycoplasma Detection Assay (Lonza) on the SpectraMax® L Microplate Luminometer
Molecular Devices
Mycoplasma infections are costly to the cell culturist as they change the morphology, viability and metabolism of the contaminated cells. Mycoplasmas are the smallest and simplest prokaryotes and depend entirely on their hosts for many nutrients due to their limited biosynthetic capabilities. Cell culture contamination by mycoplasma is difficult to detect as it does not produce pH changes or turbidity, and culture with antibiotics does little to deter this “invisible” menace.
BMG LABTECH
The BlueScreen HC assay from Gentronix utilizes a luminescence-based reporter system to measure genotoxicity. The assay generates positive results e.g for direct-acting mutagens and clastogens and correct negative results for non-carcinogens. In addition, reduced cell proliferation, a measure of cytotoxicity, is assessed, too. Using the FLUOstar Omega microplate reader from BMG LABTECH the BlueScreen HC assay has been shown to be fast, accurate and reproducible.
A Fast and Simple Method For Measuring P-Glycoprotein (Pgp) Inhibition
BMG Labtech
Pgp expression has been linked to the effl ux of chemotherapeutic drugs in human cancers leading to multidrug resistance. Pgp activity can also result in low oral absorption and poor brain penetration. Interaction of drugs with the Pgp may also cause an increase in toxicity of co-administered compounds.
Pipetting performance of Thermo Scientific Finnpipette F2 in combination with Thermo Scientific Finntip Flex
Thermo Fisher Scientific
The Finnpipette® F2 product family has been designed by taking into account the demands of today´s laboratory work and the require¬ments of the end users. It offers superior comfort, performance, reliability and repeatability in one of the lightest pipettes available.
Using a Thermo Scientific Microplate Photometer to Choose an Optimum Reagent for Cytotoxicity Assays
Thermo Fisher Scientific
A number of different reagents can be used to perform photometric cell proliferation and viability assays. A microplate photometer can quickly determine which reagent is the best choice for an assay and then optimize the assay. Significant time savings and productivity gains can be achieved with this tool.
Ergonomics and Usability Study of Thermo Scientific Finnpipette F1 and F2 Pipettes
Thermo Fisher Scientific
The objective of the study was to evaluate the ergonomics and usability of six manual, singlechannel pipettes. This was done by measuring the load and strain symptoms exhibited by workers’ muscles and joints, and evaluating the usability features of pipettes in a simulated work situation.
Antimicrobial Properties of Thermo Scientific Finnpipette F1 Compared to Traditional Pipettes
Thermo Fisher Scientific
In this application note the antimicrobial properties of the Thermo Scientific Finnpipette F1 were compared to traditional pipettes without antimicrobial treatment. The experiments were performed by an independent laboratory (Institut für Biotechnische Forschung und Entwicklung Graf GmbH, Kirkel-Limbach, Germany).
Reproducible Dispensing of Live Cells with the Thermo Scientific Multidrop Combi Reagent Dispenser
Thermo Fisher Scientific
High throughput cell-based assays are an important part of drug screening, and successfully dispensing viable cells is a key step in the process. Automated reagent dispensers are used to achieve higher throughput in the screening laboratories. Dispense must not only be quick, it must also be gentle enough to ensure cell viability.
Device Qualification of the Thermo Scientific Finnpipette Novus Electronic Pipette (IQ/OQ/PQ)
Thermo Fisher Scientific
During device qualification, one verifies and documents whether the equipment, in this case a pipette, is reliable and capable of fulfilling the requirements of its intended use. All qualification activities are fully documented according to pertinent quality and regulatory requirements and signed by authorized personnel.
Use of Thermo Scientific Finnpipette Novus Electronic Pipettes for Accurate and Efficient Preparation of Standard Curves
Thermo Fisher Scientific
This application note discusses the use of a Thermo Scientific Finnpipette Novus Electronic Pipette for the preparation of standard curves. With 10 different functions, the versatile Novus Electronic pipette can perform most every standard curve required. The pipette’s performance was compared to a manual Thermo Scientific Finnpipette model to determine if there were appreciable differences in pipetting speed and accuracy during curve preparation.
MycoAlert Mycoplasma Detection Assay (Lonza) on the SpectraMax® L Microplate Luminometer
Molecular Devices
Mycoplasma infections are costly to the cell culturist as they change the morphology, viability and metabolism of the contaminated cells. Mycoplasmas are the smallest and simplest prokaryotes and depend entirely on their hosts for many nutrients due to their limited biosynthetic capabilities. Cell culture contamination by mycoplasma is difficult to detect as it does not produce pH changes or turbidity, and culture with antibiotics does little to deter this “invisible” menace.
©2012 Technology Networks, all rights reserved.